The Anti-Diabetes Drugs market in Bosnia and Herzegovina has been experiencing steady growth in recent years.
Customer preferences: The increasing prevalence of diabetes in Bosnia and Herzegovina has led to a growing demand for anti-diabetes drugs. Patients prefer drugs that are effective in controlling blood sugar levels and have minimal side effects. They also prefer drugs that are affordable and easily accessible.
Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Bosnia and Herzegovina is the increasing use of generic drugs. Generic drugs are more affordable and offer patients a cost-effective alternative to branded drugs. This trend has been driven by the government's efforts to reduce healthcare costs and make healthcare more accessible to the general population.Another trend in the market is the growing demand for combination drugs. Combination drugs are drugs that contain two or more active ingredients. They are more effective in controlling blood sugar levels and are preferred by patients who find it difficult to manage their diabetes with a single drug.
Local special circumstances: Bosnia and Herzegovina has a high prevalence of diabetes, with an estimated 10% of the population affected by the disease. The country also has a high rate of obesity, which is a major risk factor for diabetes. The government has been taking steps to address these issues, including implementing public health campaigns to raise awareness about diabetes and promoting healthy lifestyles.
Underlying macroeconomic factors: Bosnia and Herzegovina is a developing country with a relatively low GDP per capita. The healthcare system is underfunded and patients often have to pay out of pocket for their healthcare expenses. This has led to a growing demand for affordable drugs, including generic drugs. The government has been working to improve the healthcare system and make healthcare more accessible to the general population, which is expected to drive further growth in the Anti-Diabetes Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
